The linear mixed effects model has become a standard tool for the analysis of continuous hierarchical data such as, for example, repeated measures or data from meta-analyses. However, in certain situations the model does pose unavoidable computational problems. In the context of surrogate markers, this problem has appeared when using an estimation and prediction-based approach for evaluation of surrogate endpoints. Convergence problems can occur mainly due to small between-trial variability or small number of trials. A number of alternative strategies has been proposed and studied for normally distributed data, but not such study have been conducted for other type of endpoints. The idea is to study if such simplified strategies, which always ignore individual level surrogacy, can also be applied when both surrogate and true endpoints are of failure-time types. It is shown via simulations that the 3 simplified strategies produced biased estimates, especially for the cases in which the strength of individual-level association is different from the strength of trial-level association. For this reason, it is recommended not to use simplified strategies when dealing with failure time data, in contrast to the case of normally distributed data, for which simplified strategies are recommended. Possible reasons for this discrepancy might be that, in this case, ignoring the individual level association influences estimates of the mean structure parameters, what results in distorted estimates of the trial level association.
Introduction
Surrogate endpoints can replace or supplement other endpoints in the evaluation of experimental treatments or other interventions. For example, surrogate endpoints are useful when they can be measured earlier, more conveniently, or more frequently than the endpoints of interest, which are referred to as the "true" endpoints (Ellenberg and Hamilton, 1989) . A number of approaches appeared at the end of eighties to deal with this type of problems. Prentice (1989) and Freedman, Graubard and Schatzkin (1992) laid the foundations for the evaluation of surrogate endpoints in randomized clinical studies. Prentice proposed a definition as well as a set of operational criteria. Freedman, Graubard and Schatzkin (1992) supplemented these criteria with a quantity called proportion explained (PE). Buyse and Molenberghs (1998) , on the other hand proposed to replace the PE by the relative effect (RE), linking the effect of treatment on both endpoints, and an individual-level measure of agreement between both endpoints, after adjusting for the effect of treatment (adjusted association). The adjusted association carries over when data are available on several randomized trials, while the RE can be extended to a trial-level measure of agreement between the effects of treatment of both endpoints. Molenberghs et al. (2002) and Alonso et al. (2004) pointed out serious issues surrounding the Prentice-Freedman framework. It has been asserted that the criteria set out by Prentice are too stringent (Fleming and DeMets, 1996) and neither necessary nor sufficient for his definition to be fulfilled, except in the special case of binary outcomes (Buyse and Molenberghs, 1998) . In addition, Freedman, Graubard and Schatzkin (1992) showed that these criteria were not straightforward to verify through statistical hypothesis tests. Therefore the PE was suggested, but this measure is surrounded with difficulties, the most dramatic being not confined to the unit interval (Buyse et al., 2000) . Buyse et al. (2000) argued that some fundamental criticisms towards the process of statistical validation can be overcome by combining evidence from several clinical trials, such as in a meta-analysis, rather than from a single study. To this end, they needed to formulate a bivariate hierarchical model, accommodating the surrogate and true endpoints in a multi-trial setting. Assuming normality, they carried over the relative effect and adjusted association to a trial-level R 2 trial and an individual-level R 2 indiv , respectively. Similar routes of meta-analytic thinking have been followed by Daniels and Hughes (1997) and Gail et al. (2000) .
Of course, the switch to a meta-analytic framework does not solve all problems, surrounding surrogate marker validation, in a definitive way. First, one has to carefully reflect upon the question as to how broad the class of treatments and units, to be included in a validation study, can be. Clearly, the issue disappears when the same or similar treatments are considered across units (e.g., in multi-center or multi-investigator studies, or when data are used from a family of related studies such as in a single drug development line). In a more loosely connected, meta-analytic setting it is important to ensure that treatment assignments are logically consistent. This is possible, for example, when the same standard treatment is compared to members of a class of experimental therapies.
A result of the change to meta-analysis is that computationally rather involved statistical models have to be used. For the case of surrogates and true endpoints that are both normally distributed, Buyse et al. (2000) employed linear mixed effects models (Verbeke and Molenberghs, 2000) . Even in this case, which can be considered a basic one from a statistical modeling point of view, fitting such linear mixed effects models turns out to be surprisingly difficult. In order to overcome computational burden Tibaldi et al. (2003) proposed a set of simplified strategies for this particular setting. In other settings, e.g., when both endpoints are failure-times, the use of a mixed effects model is even less straightforward.
The aim of the paper is to study the possibility of also using simplified strategies when both the surrogate and the true endpoints are of the failure-time types. In 2001, Burzykowski in his dissertation already proposed a simplified strategy in this scenario and performed a simulation study, in which a copula model was used to assess the association at the individual level, and a fixed effects model was employed to assess the trial level surrogacy. In this paper we will study simplified modeling strategies that ignore the individual level association to evaluate the trial level surrogacy, following similar ideas as in Tibaldi et al. (2003) . A simulation study is carried out to evaluate the performance of the different simplified strategies, in the setting studied by . The idea of the paper is to show that even when simplified strategies performed well in the scenario of normally distributed endpoints, they should be carefully investigated in other scenarios, because they might produce biased results. This paper is organized as follows. First, we present the original setting proposed by Buyse et al. (2000) and the simplified strategies considered by Tibaldi et al. (2003) (Sections 2 and 3), then extension to the setting for which both endpoints are of failure-time type, and which will be used throughout the paper is presented (Section 4). In Section 5 we describe the strategies that will be used to estimate the parameters of interest. A brief description of the method proposed by is presented in Section 6, follow by the description of the simulation study considered (Section 7). The results obtained are described in Section 8. Discussion in Section 9 concludes the paper.
Setting for Normally Distributed Endpoints
In this section we briefly described the approach proposed by Buyse et al. (2000) in order to study in details the extension for failure-time data. Let Y T ij and Y S ij be random variables denoting the true and the surrogate endpoints for subject j = 1, . . . n i in trial i = 1, . . . N. Further, let Z ij denote a binary treatment indicator.
The full random-effects model, as introduced by Buyse et al. (2000) , is given by
where µ S and µ T are fixed intercepts, m S i and m T i are random intercepts for trial i, α and β are fixed treatment effects and a i and b i are random treatment effects. The individual-specific error terms are ε S ij and ε T ij , which are zeromean normally distributed with variance-covariance matrix
The vector of random effects, (m S i , m T i , a i , b i ) T , is also assumed to be zeromean normally distributed with variance-covariance matrix Buyse et al. (2000) proposed a measure to assess the quality of the surrogate at the trial level, based on the coefficient of determination
A good surrogate, at the trial level , would have (5) close to 1. Similarly, to measure individual-level surrogacy, Buyse et al. (2000) proposed to use the coefficient of determination given by
where σ ST , σ SS and σ T T are components of variance-covariance matrix (3). The authors also proposed a reduce version to evaluate trial-level surrogacy which is given by the following expression
This formula is useful when the full random-effects model is hard to fit but a reduced version, excluding random intercepts, is easier to reach convergence. Ample details about the approach can be found in Buyse et al. (2000) .
Simplified Modelling Strategies
Buyse et al. (2000) showed that fitting mixed effects model (1)-(2) can be a surprisingly difficult task in a number of situations. Especially when the number of trials or the number of patients per trial is small. Also, situations with extreme correlations pose problems. It is therefore that approximate strategies with better computational properties have been studied for this particular setting in which both endpoints are normally distributed. Tibaldi et al. (2003) consider three dimensions along which simplifications that can be made in order to deal with computational burden in such setting.
Trial dimension: for which the trial-specific effects can be treated as either random or fixed. Endpoint dimension: the surrogate and true endpoints are modelled as a bivariate outcome or two univariate ones. In the latter case the individuallevel surrogacy is not incorporated into the modeling strategy. However, throughout this paper the focus is on trial-level surrogacy. Measurement error dimension: whenever the full mixed effects model is abandoned, measurement error arises. The authors consider three ways to account for measurement error: unadjusted (i.e., no correction at all), adjustment by trial size, and an approach suggested by Van Houwelingen, Arends and Stijnen (2001) .
Extension to Failure-Time Endpoints
In order to extend the meta-analytic approach used in the case of two normallydistributed endpoints described in Section (2), one could consider replacing model (1)- (2) by the following mixed effects proportional hazards model:
where i indexes the trials, j indexes the subjects and, as in Section (2), m S i and m T i are random intercepts for trial i, α and β are fixed treatment effects and a i and b i are trial specific random treatment effects. The vector of random effects, (
T , is assumed to be zero-mean normally distributed with variance-covariance matrix
The random effects ε ij are chosen to induce individual-level association between Y S ij and Y T ij . The major stumbling block in the use of model (8)- (9) is the presence of individual random effects ε ij . Given the current methodology and available software, fitting the model is practically impossible. Therefore, we will focus on strategies that ignore the association at the individual level and concentrate on the evaluation of trial level surrogacy. In the next section we will briefly describe the simplified strategies considered which focus on endpoint and trial dimension previously presented.
Modelling Strategies
We will consider the following three modelling strategies, in which the individuallevel association is ignored.
Marginal PH Model with Trial-Specific Fixed Effects (MFE).
A Cox proportional hazards model will be fitted separately for each trial and also for each endpoint. More specifically, the model can be written as
where α i , and β i are trial-specific treatment effects. Similar to the approach proposed by Buyse et al. (2000) for the case of two normally distributed endpoints, at the second stage we compute the determination coefficient (R
) from the regression of β i on α i . To compute its variance we first use the delta method and treat the determination coefficient as a function of the correlation
Var(R trial (r) ).
Then we use the fact that the variance of Fisher'
is equal to 1958, p.78) . Now, R trial (r) can be rewritten as a function of Z R trial (r) = e 2Z − 1 e 2Z + 1 , so, using the delta method and treating R trial (r) as a function of Z, we get
Combining (13) and (14) leads to
A Stratified PH Model with Random Trial-Specific Treatment Effects (SRTE).
In this model we use stratified baseline hazards to account for the betweentrial variability in baseline hazards, and bivariate random effects associated to the treatment. The model can be written as follows:
where α and β are fixed treatment effects. The trial specific random effects a i and b i are assumed to be zero-mean normally distributed with variance-covariance matrix
The trial-level validity of a surrogate is evaluated using the square of the correlation coefficient based on the estimated variance-covariance matrix (17). Its variance is estimated using equation (13), with Var(R trial (r) ) estimated by applying the delta method to R trial (r) treated as a function of the estimated elements of matrix (17).
PH Model with Trial-Specific Random Intercepts and Treatment Effects (RITE).
In this model we consider both random intercepts and treatment effects. The model is:
where
T is a vector of random effects, assumed to be zero-mean normally distributed with variance-covariance matrix (10) . The association at the trial level is evaluated using the determination coefficient computed using equation (7). The variance of the coefficient is estimated using the same procedure as in strategy SRTE.
The models were fitted using the SAS procedure PHREG for the MFE approach and the modified version of the EM algorithm (as described in Cortiñas and Burzykowski (2005) , we only considered this approach given that in a comparison performed by Cortiñas et al. (2007) the estimated values for fixed and random effects were comparable), implemented using SAS-IML v8.2, for the SRTE and RITE approaches. We will compare the performance of the simplified strategies with the approach developed by , which we describe in the next Section. assumed that the variables Y T ij (the true endpoint) and Y S ij (the surrogate endpoint) were distributed according to a bivariate distribution with the joint survival function
A Copula Modelling Approach
where C θ {., .} is a copula function. In particular, they considered the use of the Clayton copula
The marginal survivor functions F Y S ij (y S ij ) and F Y T ij (y T ij ) were modeled using PH models. The use of the copula allows to assess the individual-level surrogacy by Kendall's τ , which for the Clayton copula (21) can be computed as a simple function of θ:
Furthermore, Y T ij and Y S ij were assumed to be exponentially distributed, with the marginal survivor functions F Y T ij and F Y S ij defined as
where i indexes the trials, j indexes the subjects, m S i and m T i are random intercepts for trial i, α and β are fixed treatment effects and a i and b i are trial specific random treatment effects. The vector of random effects, (m S i , m T i , a i , b i ) T , was also assumed to be zero-mean normally distributed with variance-covariance matrix (10) .
Variables Y T ij and Y S ij are assumed exponentially distributed with marginal survival functions given by (22)- (23) and the joint survival function (20)- (21), were generated using the conditional distribution method (Nelsen , 1999) . Note, that the marginal survivor functions are also conditional on the random effects m S i , m T i , a i and b i . proposed to use the maximum likelihood estimates of the parameters of model (20)- (21), assuming the fixed effects representation of (22)-(23)
In (20), trial-specific treatment effects were estimated as fixed effects α i and β i in the marginal PH models for F Y S ij (y S ij ) and F Y T ij (y T ij ), respectively. The trial level surrogacy was evaluated using the determination coefficient from the linear regression of β i on α i .
The main advantage of the approach proposed by is that it does allow for the evaluation of the individual level association. However, in the approach treatment effects are modelled as fixed rather than random effects. The strategies proposed in Section 5 (SRTE and RITE) use random effects at the trial level, but ignore individual level association. The question is, how much does this influence the performance of the simplified strategies. To answer this question, a simulation study is conducted.
Simulation Study
To investigate the performance of the various strategies presented in Section 5, a simulation study was undertaken. The strategies were compared against each other and against the copula approach developed by . In the simulations, data for N randomized clinical trials with n i observations (subjects) within a trial were generated. A single binary covariate Z ij was considered, corresponding to a treatment randomization within each trial. The data were generated using model (8)- (9), exponential marginal models were considered and the baseline hazards were assumed constant, with λ S (y S ij ) = 0.69 and λ T (y T ij ) = 1.39, resulting in median times equal to 1 and 0.5 respectively. Two settings for treatment effects were considered: α = β = 0 (no treatment effect) or α = β = −0.4 (corresponding to 33% reduction in failure rate). The variance-covariance matrix of the normally distributed random effects (m S i , m T i , a i , b i ) T , was assumed to be equal to
The value of σ 2 was set to equal 0.2, while ρ was set to √ 0.5 or √ 0.9, resulting in the trial-level R 2 trial (r) of 0.5 and 0.9, respectively. The individual random effects ε ij were considered gamma distributed with density function
In this way, the data generated using model (8)-(9) were comparable to those generated by using the Clayton copula (21). Two hundred and fifty datasets were simulated for every setting, with N = 10 or N = 20 trials each. The number n i of observations (subjects) per trial was assumed to equal 50, 100 and 200. The copula parameter θ was assumed equal to 3 or 19, resulting in Kendall's τ of 0.5 and 0.9, respectively, for the association between Y T ij and Y S ij (conditional on the random effects m S i , m T i , a i and b i ). We considered no censoring or homogeneous censoring. In the latter set-up, Y T ij and Y S ij were assumed to be simultaneously censored by an independent variable C ij uniformly distributed on the interval [0, δ c ]. The parameter δ c was chosen to be 2.3 for α = β = 0, resulting in 50 % of the observations of Y T ij (the true endpoint) and 30 % of the observations of Y S ij (the surrogate endpoint) censored, similar to the censoring schemes considered by .
Results of the Simulation Study
The results of the simulations are shown in Tables 1-4, note that column quoted as Burzykowski means that we displayed the results obtained by for the case of unadjusted R 2 ; MFE refers to marginal PH model with trial-specific fixed effects; SRTE to stratified PH model with random trialspecific treatment effects and RITE to PH model with trial-specific random intercepts and treatment effects results. The %NC represents the % of samples with non-convergence and %bias the bias relative to the true value of the parameter (in %). The tables show the relative bias of R for different values of τ , R 2 trial (r) (= ρ 2 ), α, β, and different censoring schemes. It is worth noting that the results displayed for the method proposed by are based on 500 simulations. For the latter method and τ = 0.9 the percentage of samples with non-convergence is also shown (for τ = 0.5 there were no convergence problems). The simplified strategies proposed in Section 5 do not suffer from convergence problems. No censoring, no treatment effect (α = β = 0) Table 2 The mean estimates of trial level R 2 trial (r) for the method proposed by and the simplified strategies when τ = 0.5 and R 2 trial (r) = ρ 2 = 0.9. In parentheses: the mean model-based and empirical (first and second number) standard error.
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MFE SRTE RITE
N n i %bias %bias %bias %bias
No censoring, no treatment effect (α = β = 0) Table 4 The mean estimates of trial level R 2 trial (r) for the method proposed by and the simplified strategies when τ = 0.9 and R 2 trial (r) = ρ 2 = 0.5. In parentheses: the mean model-based and empirical (first and second number) standard error. . Also, under no censoring the relative bias in absolute value is smaller than when censoring is considered. One can also observe that for MFE, model-based estimates of the standard error of R Table 1 shows the simulation results for τ = 0.5 and ρ 2 = 0.5. In terms of point estimation it can be seen that, in general, RITE approach yields the smallest relative bias in absolute value, followed by SRTE approach, while the largest bias is observed for MFE approach. It can also be noted that the RITE and SRTE approaches are subject to similar empirical variability as in the method proposed by , with the MFE approach showing larger variability. For the other settings (Tables 2-4) , in general, the smallest relative bias in absolute value is observed for the method proposed by , while the MFE approach yields estimates with the largest relative bias in absolute value. It is worth noting that the three simplified strategies produce substantially biased estimates of R 2 trial (r) when the association at the individual level (measured by τ ) and the association at the trial level (measured by ρ 2 ) are different. It can be also observed that if ρ 2 = 0.9, the approach produces estimates with the smallest empirical standard error, while the MFE approach produces estimates with the largest standard errors. If ρ 2 = 0.5, the RITE approach yields estimates with the smallest variability, while the approach proposed by produces estimates with the largest variability. It is important to note that for different values of ρ 2 when the value of τ is kept the same, only moderate changes in the magnitude of the variability of the estimates produced by the simplified strategies are observed. Thus, if the individual level is ignored in the fitting process, the value of τ may determine the magnitude of the variability of the estimates. From the evaluation of the relative bias one can conclude that the use of the simplified strategies does not yield reasonable results. This is in contrast to the case of normally distributed data considered by Tibaldi et al. (2003) . In order to investigate the cause of the large relative bias in absolute value produced by the simplified strategies, we evaluated the estimated cumulative baseline hazards when the RITE approach was used for two particular settings under no censoring (Setting I: N = 20, n i = 50, τ = 0.5, ρ 2 = 0.9; Setting II: N = 20, n i = 50, τ = 0.9, ρ 2 = 0.5). Figure 1 shows the estimated cumulative baseline hazard functions (step curves) versus the observed time for both endpoints and settings I and II. From this figure, it can be concluded that the estimated cumulative baseline hazards do not correspond to the true cumulative hazard function (thick solid line) used to generate the data. This suggests that ignoring individual level association results in a strong modification of the baseline hazard. Consequently, the estimates of the mean structure parameters are affected, which in turn influences the trial-specific treatment effects and the estimation of the trial-level association in MFE approach. It is also important to note that Cortiñas et al. (2004) have also observed similar problems, when they fitted a hierarchical model ignoring a level, and the variance associated to the level was of the same magnitude or larger than the variance at the higher level, the association at the higher level was affected. Here a similar pattern can be observed. When ε ij is gamma-distributed with density function (27), the logarithm of ε ij will have variance ψ ′ (
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), where ψ ′ () is the trigamma function (Johnson and Kotz, 1970, p. 181) Top row: τ = 0.5 and ρ 2 = 0.9; bottom row: τ = 0.9 and ρ 2 = 0.5.
Conclusions
In this paper we have investigated the use of several strategies for the evaluation of the trial level surrogacy in the case of two failure-time endpoints. In particular, we have considered three strategies which may reduce the computational burden and the complexity of the model. The first one (marginal PH model with trial-specific fixed effects) is a very simple procedure, which can easily be implemented with standard software. This model is comparable to the simplest model used in Tibaldi et al. (2003) , in which only fixed effects are used, every endpoint is modeled separately, and we do not adjust for measurement errors. In the second strategy, random effects are considered, but stratified baseline hazards are used in order to capture the between-trial variability in baseline hazards (SRTE). The third strategy is a PH model with trial-specific random intercepts and treatment effects (RITE). It is shown via simulations that the three simplified strategies produce highly biased estimates, especially for the cases in which the strength of the individual-level association is different from the strength of the trial-level association. For this reason, the simplified strategies should not be used in the case of two failure time endpoints. This is in contrast to the case of normally distributed data (see Tibaldi et al. (2003) , for more details). In this scenario simplified modeling strategies produce untrustful results, thus they should not be employed to evaluate surrogacy. For the MFE approach the possible reason for this discrepancy is that, in the case of failure-time data, ignoring the individual level association influences estimates of the mean structure parameters, what results in distorted estimates of the trial level association. It is important to note that, in this paper we did not study methods that correct for measurement error, as it has been done in Tibaldi et al. (2003) . In this respect, a GEE approach might be of interest. This is a topic for further research. Another way of handling the complexities in the model is to use a bayesian modeling framework, which could handle the hierarchical structure on the hazard scale very easily, but this is out of the scope of the paper, since we would like to be able to use easy to implement procedures in standard software, but unfortunately in this setting with two failure time endpoints simplified strategies do not provide promising results.
